Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Outlook Therapeutics Inc 485 ROUTE 1 SOUTH BUILDING F SUITE 320 ISELIN NJ 08830 USA

www.outlooktherapeutics.com P: 609-619-3990

Description:

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.

Key Statistics

Overview:

Market Capitalization, $K 100,590
Enterprise Value, $K 112,750
Shares Outstanding, K 13,013
Annual Sales, $ 0 K
Annual Net Income, $ -58,980 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -11,180 K
EBIT, $ -47,760 K
EBITDA, $ -47,720 K
60-Month Beta 0.28
% of Insider Shareholders 5.30%
% of Institutional Shareholders 11.20%
Float, K 12,323
% Float 94.70%
Short Volume Ratio 0.64

Growth:

1-Year Return -67.99%
3-Year Return -81.51%
5-Year Return -81.60%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 97.78%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.80 on 02/14/24
Latest Earnings Date 05/20/24
Earnings Per Share ttm -4.00
EPS Growth vs. Prev Qtr 20.00%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 03/14/24

OTLK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -132.37%
Profit Margin % 0.00%
Debt/Equity -1.50
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.87
Interest Coverage -36.81
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar